Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation.

Saved in:
Bibliographic Details
Title: Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation.
Authors: Siegert E; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Biesen R; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Dzamukova M; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Rheumatology Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany., Furth C; Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Probst M; Department of Infectious Diseases, Respiratory and Critical Care Medicine, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Doellinger F; Department of Radiology, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Walter-Rittel T; Department of Radiology, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Fleischmann A; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Rheumatology Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany., Wilhelm A; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Rheumatology Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany., Beenken AE; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Rheumatology Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany., Wiebe E; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Pecher AC; Center for Interdisciplinary Rheumatology, Immunology and Autoimmune Diseases (INDIRA) and Department for Internal Medicine II (Hematology, Oncology, Rheumatology and Immunology), Universitätsklinikum Tübingen, Tübingen, Germany., Henes J; Center for Interdisciplinary Rheumatology, Immunology and Autoimmune Diseases (INDIRA) and Department for Internal Medicine II (Hematology, Oncology, Rheumatology and Immunology), Universitätsklinikum Tübingen, Tübingen, Germany., Florian S; Institute of Pathology, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Simon D; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Kleyer A; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Burmester GR; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Rheumatology Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany., Keller U; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Center for Translational Cancer Research (DKTK), Partner Site Berlin, Berlin, Germany., Krönke J; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Center for Translational Cancer Research (DKTK), Partner Site Berlin, Berlin, Germany., Krönke G; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Rheumatology Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany., Alexander T; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Rheumatology Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany. Electronic address: tobias.alexander@charite.de.
Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2025 Apr; Vol. 84 (4), pp. 653-656. Date of Electronic Publication: 2025 Feb 24.
Publication Type: Letter
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1468-2060
DOI:10.1016/j.ard.2025.01.043